The transcription of the human UCP3 gene in skeletal muscle is tightly regulated by metabolic signals related to fatty acid availability. However, changes in thyroid status also modulate UCP3 gene expression, albeit by unknown mechanisms. We created transgenic mice bearing the entire human UCP3 gene to investigate the effect of thyroid hormones on human UCP3 gene expression. Treatment of human UCP3 transgenic mice with thyroid hormones induced the expression of the human gene in skeletal muscle. In addition, transient transfection experiments demonstrate that thyroid hormones activate the transcription of the human UCP3 gene promoter when MyoD and the thyroid hormone receptor were co-transfected. The action of thyroid hormones on UCP3 gene transcription is mediated by the binding of the thyroid hormone receptor to a proximal region in the UCP3 gene promoter that contains a direct repeat structure. An intact DNA sequence of this site is required for thyroid hormone responsiveness and thyroid hormone receptor binding. Chromatin immunoprecipitation assays revealed that the thyroid hormone receptor binds this element "in vivo". The murine UCP3 gene promoter was also dependent on MyoD and responsive to thyroid hormone in transient transfection assays. However, it was much less sensitive to thyroid hormone than the human UCP3 promoter. In summary, UCP3 gene transcription is activated by thyroid hormone treatment "in vivo" and this activation is mediated by a thyroid hormone response element in the proximal promoter region. Such regulation suggests a link between UCP3 gene expression and the effects of thyroid hormone on mitochondrial function in skeletal muscle.
SYNOPSIS
The transcription of the human UCP3 gene in skeletal muscle is tightly regulated by metabolic signals related to fatty acid availability. However, changes in thyroid status also modulate UCP3 gene expression, albeit by unknown mechanisms. We created transgenic mice bearing the entire human UCP3 gene to investigate the effect of thyroid hormones on human UCP3 gene expression. Treatment of human UCP3 transgenic mice with thyroid hormones induced the expression of the human gene in skeletal muscle. In addition, transient transfection experiments demonstrate that thyroid hormones activate the transcription of the human UCP3 gene promoter when MyoD and the thyroid hormone receptor were co-transfected. The action of thyroid hormones on UCP3 gene transcription is mediated by the binding of the thyroid hormone receptor to a proximal region in the UCP3 gene promoter that contains a direct repeat structure. An intact DNA sequence of this site is required for thyroid hormone responsiveness and thyroid hormone receptor binding. Chromatin immunoprecipitation assays revealed that the thyroid hormone receptor binds this element "in vivo". The murine UCP3 gene promoter was also dependent on MyoD and responsive to thyroid hormone in transient transfection assays. However, it was much less sensitive to thyroid hormone than the human UCP3 promoter. In summary, UCP3 gene transcription is activated by thyroid hormone treatment "in vivo" and this activation is mediated by a thyroid hormone response element in the proximal promoter region. Such regulation suggests a link between UCP3 gene expression and the effects of thyroid hormone on mitochondrial function in skeletal muscle.
INTRODUCTION
Thyroid hormones regulate energy metabolism by increasing respiration and energy expenditure and by lowering metabolic efficiency. Although this has been known for years, the molecular mechanisms for these effects of thyroid hormones remain to be established. In rodents, thyroid hormones affect the energy metabolism by altering the proton leak across the inner mitochondrial membrane through unknown mechanisms (1;2). Thyroid hormones exert most of their known biological effects through the stimulus of gene transcription but the key target genes of thyroid hormones involved in energy metabolism and metabolic efficiency changes remain unidentified.
The discovery of mitochondrial uncoupling proteins 2 and 3, which are closely similar to the thermogenic brown fat uncoupling protein-1 suggested that these proteins are potential targets of thyroid hormone effects and mediators of the thyroid action promoting energy expenditure (3) . This research has been especially active after the finding that UCP3 gene expression in muscle is extremely sensitive to the thyroid hormone status in rodents. Thus, early after the discovery of UCP3, it was reported that the administration of thyroid hormones to rodents enhances the expression of UCP3 in skeletal muscle, which is paralleled by a rise in resting metabolic rate (4;5).
Experiments using rodents at extreme thyroid status situations (profound hypo-or hyperthyroid) support the major effect of thyroid status on UCP3 gene expression (6;7).
Human UCP3 gene transcription is regulated by fatty acids and retinoic acid, as reported elsewhere (8;9) but the action of thyroid hormone has not been established.
Although individual variations in UCP3 mRNA levels in skeletal muscle do not correlate with changes in circulating thyroid hormones in euthyroid healthy subjects (10) a doubling of T3 levels induced in volunteers led to an up-regulation of UCP3 mRNA abundance in skeletal muscle (11) . Moreover, UCP3 has been recently reported as a thyroid-sensitive gene in a microarray study of cDNAs from human muscle (12) . However, the mechanisms by which thyroid status modulates UCP3 gene expression are unclear.
Results from cultured rodent myogenic cell lines indicate a positive effect of T3 on UCP3 mRNA levels, thus supporting a direct action of thyroid hormones in UCP3 gene expression (13) . In human myotubes, differentiated in culture, UCP3 mRNA expression is moderately increased after exposure to thyroid hormones (11) . The involvement of transcriptional and/or post-transcriptional mechanisms in the effects on 3 steady-state UCP3 mRNA levels has not been elucidated and the corresponding experimental approaches have been dampened by the extremely low levels of expression of the human UCP3 gene in cultured myotubes compared with skeletal muscle "in vivo" (8;11;14) .
Here, we created a human UCP3 transgenic mouse and showed that thyroid hormones induce the tissue-specific expression of the human UCP3 gene. Moreover, T3 directly induced the expression of the human UCP3 gene through a multi-hormonal response element in the proximal promoter region of UCP3.
EXPERIMENTAL PROCEDURES
Human UCP3 transgenic mice. HUCP3 transgenic mice were generated using standard procedures described elsewhere (15) . A genomic P1 clone (plate 324 and well H6) containing human UCP3 (16) was mapped by restriction enzyme analysis and microinjected into pronuclei of fertilized FVB mouse oocytes. Transgenic offspring were identified using standard Southern Blot analysis. Genomic DNA was isolated from the tail of mice and restriction analysis was performed using Xba I. Membranes were hybridised with a probe corresponding to human UCP3 exon 1 (200bp, from -181 bp 5' of the start codon to 18 bp 3' of the start codon, accession number AF001787).
Transgenic offspring were examined for the presence of a 2.9 kb band which was absent in the non-transgenic littermates. Two lines (TgA and TgB) from two different founders were analysed and used in the present study.
Analysis of human UCP3 mRNA transcripts by RNAse protection assay. RNAse assay was performed as previously described, using an in vitro transcribed [32P]-labeled RNA antisense probe corresponding to human UCP3 long form (17) , spanning exons 6 and 7 (+631 to +925 relative to ATG). Analysis was performed using 10 and 20 µg of RNA and protected bands for UCP3 L and UCP3 S (16) were visualized by autoradiography.
Northern blot analysis of human UCP3 mRNA. Mice were housed with free access to standard rodent chow and water. For starvation experiments food was removed for 18 hours. For thyroid hormone treatment, control and transgenic mice were treated either with saline or T3 (100 µg/Kg) i.p. and studied 18 hours later. In both cases, animals were sacrificed and tissues were harvested. RNA was prepared with RNAzol (Cinna/Biotecx Laboratory, Houston, TX) except for human skeletal muscle RNA which was obtained from Clontech and used for comparative purposes. 20 µg RNA was loaded for Northern blot analysis. Hybridization was performed by standard methods and ethidium bromide staining was used to confirm equal loading of RNA.
Hybridization probe was generated by random priming from cDNA template of human UCP3 (described above). To quantify mRNA expression, Northern blots were analysed using Phosphoimager (Molecular Dynamics, Image Quant software).
Construction of transfection plasmids.
Fragments from -4511 to +47 and from -2903 to +47 of the human UCP3 promoter were amplified by PCR and were cloned into pGL3 basic to generate -4511hUCP3-luc and -2903hUCP3-luc respectively. From -2903hUCP3-Luc, a SacI restriction and re-ligation generates the -1588hUCP3-Luc construct, and the rest of the constructs were generated according to a previous report (8) Further experiments were performed using two transgenic lines, A and B. The expression of hUCP3 mRNA was predominant in skeletal muscle in transgenic mice and no detectable levels of hUCP3 mRNA were found in white adipose tissue, brown adipose tissue or heart ( Fig 1A) . The levels of human UCP3 mRNA in transgenic mice were similar to those observed in human skeletal muscle samples (82 ± 15 %).
Moreover, both the long and the short form of hUCP3 mRNA transcripts were expressed in hUCP3 transgenic mice, as revealed by the RNAse protection assay ( Fig   1A) . This finding is in agreement with the observation that human skeletal muscle contains both forms of UCP3 transcripts (16) .
Mice UCP3 gene expression is up-regulated in skeletal muscle during starvation (4). Thus, we tested whether the expression of the human UCP3 gene was also regulated during starvation in transgenic mice. For this purpose, food was removed from transgenic mice for 18 h and RNA was isolated from skeletal muscle. Northern blot analysis was performed using a probe specific for human UCP3 mRNA, generated as described in Methods, to avoid cross-hybridization of the human transcripts with mouse UCP3 mRNA (Fig 1B) . Northern blot analysis detected the expression of the human UCP3 mRNA transcripts as a single band given the small difference in size between UCP3L and UCP3S mRNAs (100bp). In both lines, A and B, human UCP3 mRNA levels from starved transgenic mice were a 5.8 and 6.5 fold higher, respectively, than human UCP3 mRNA from fed transgenic littermates (Fig 1B) . Using a specific probe to detect exclusively the mouse UCP3 transcripts, a similar induction was observed for mouse UCP3 mRNA due to fasting (data not shown). Therefore, the human UCP3 transgene is not only expressed in a tissue-specific manner but is also regulated by changes in the physiological status.
T3 treatment induces human UCP3 gene expression in transgenic mice. We then analyzed the effect of thyroid hormone treatment "in vivo" on the human gene in the transgenic mice. A dose of 100 µg of T3 /kg or saline as a control was injected intraperitoneally to transgenic mice. Eighteen hours later mice were killed, hindlimb skeletal muscle extracted and RNA was analyzed by Northern blot using the humanspecific probe as described above. Human UCP3 mRNA in skeletal muscle was significantly induced in both transgenic lines (A by 4.5 fold and B by 3,3 fold respectively) (Fig 2) . As performed for starvation experiments, a specific probe was used to detect the mouse UCP3 mRNA. In our conditions, mouse UCP3 mRNA was not Data from computer analysis of the 5' non-coding region of the human UCP3 gene reveal four potential thyroid hormone response elements (TREs) in the promoter (24;25) (Fig 4) . Thereafter, we assayed serial deletions of the human UCP3 5' region from -4.5 kb to a -165 bp construct, which were activated by T3 with a similar foldinduction respect to the 4.5 kb hUCP3-Luc. When the fragment between -165 to -61 was deleted, responsiveness to T3 was lost (Fig 4) . These results indicate that the element responsible for T3 response is located within the proximal region. This region (from -165 to +47) of the human UCP3 promoter contains TRE1, a DNA element responsive to retinoic acid as well as to PPAR agonists, with an imperfect structure of direct repeat with one base spacing (8;9). Point-mutant analysis of this TRE1 element was undertaken to establish whether it is also responsible for mediating the effect of T3.
The wild type construct -165hUCP3Luc responded to T3, whereas the mutant165hUCP3mutTRE1hUCP3-Luc was not significantly induced by the hormone (Fig 4) .
The same result was obtained when the point mutation was introduced into the1588hUCP3 plasmid, thus indicating that the TRE1 element located at -71 to -59 is essential for the human UCP3 gene to respond to thyroid hormone. The results obtained using UCP3-TRE1m2 were similar to those obtained with the wild type oligonucleotide, suggesting that although the site 2 was mutated, binding of the TR alone or TR-RXR still occurred. In addition, we performed competition experiments using labeled UCP3-TRE1 always in presence of RXR and TR (Fig 5C) . When the non-labeled UCP3-TRE1 oligonucleotide was used for competition, the amount of the DNA-protein complex decreased as increasing amounts of non-labeled oligonucleotide were added. The bands disappeared completely at 100-fold excess of cold oligonucleotide, pointing to the specificity of the binding of the TR and TR-RXR complexes to the TRE1 element. When the competition assay was performed using UCP3-TRE1m1, even at 100-fold excess all retarded DNA-protein complexes were still formed. Thus, there was no competition between the oligonucleotides by the nuclear proteins bound at the specific site when the AGGTCA half site was mutated. As expected from the previous results, competition with UCP3-TRE1m2 showed the same results as the wild type.
To further support these results, we checked whether the thyroid receptor present in L6 nuclear extracts binds to this site. Briefly, the UCP3-TRE1 labeled oligonucleotide was incubated with 5 µg of protein extracts from L6. Upon incubation with nuclear extracts, one major band and three other retarded bands were formed.
When a specific antibody against TR was added to the incubation media, the intensity of i and ii bands decreased, and a new band of lower mobility, marked as S, was formed.
( Fig 5D) . Of note, only the reduction in the i band was specific, since the ii band also disappeared when CEBPα antibody was added as a negative control. Therefore, the i band is formed by a DNA-protein complex containing TR, thus indicating that TR binds the hUCP3 TRE1 site.
In vivo binding of TR to the TRE1 element by Chromatin
Immunoprecipitation assay. We next examined the interaction of TR with the human UCP3 promoter "in vivo". We performed Chromatin Immunoprecipitation (ChIP) assays on transfected L6 cells with two human UCP3 reporter constructs, the wild type (-1588hUCP3-Luc) and the one containing the mutation in the TRE1 site (-1588mutTRE1hUCP3-Luc) always in the presence of MyoD and TRβ1.
Immunoprecipitation of protein-DNA complexes with the TR antibody caused a specific enrichment of the 191 bp PCR product corresponding to the -166 to +26 region of the hUCP3 gene in the wild type construct when compared with the control with IgG antibody (Fig 6) . Correspondingly, when the TR antibody was added to the protein-DNA complexes from cells transfected with the mutated TRE1 construct, the specific band was not enriched. These results confirm that TR binds "in vivo" to TRE1 in the human UCP3 promoter.
The mouse UCP3 promoter is also activated by thyroid hormone but it is less sensitive than the human promoter. In order to explore the basis of the higher effects of T3 observed in the human UCP3 transgene respect to the endogenous mouse UCP3 gene, we cloned a 2 kb fragment of the 5' non-coding region of the mouse UCP3 gene upstream the transcription initiation site. When transiently transfected into L6 cells, the mouse UCP3 promoter showed low basal expression levels but it was strongly induced by co-transfected MyoD, to a similar extent to that observed in the human UCP3 promoter. When TR was co-transfected, T3 induced the mouse UCP3 promoter activity by 2 fold. This induction is significantly lower than the induction observed in the human UCP3 promoter (Fig 7A) . This result was also confirmed in dose-response curves where induction of the mouse UCP3 promoter by T3 was lower than in the human UCP3 promoter at all T3 concentrations tested (Fig 7B) . This lower sensitivity did not depend on the subtype of TR receptor co-transfected as it was equally observed when co-transfecting chicken TRα promoter region with a similar sequence to the TRE1 previously characterized in the human gene (see Fig 7C) . Point mutation of this region abolished the responsiveness of the mouse UCP3 promoter to T3 (Fig 7D) (as also happened with the human UCP3 promoter, Fig 4) , thus indicating that this site behaves as a TRE in the mouse UCP3
promoter. Band shift analysis of this site in comparison with the human TRE1 indicated that the binding observed in the mouse TRE was weaker, especially the bands III and IV corresponding to TR/RXR heterodimers which were almost undetectable (Fig 7E) .
DISCUSSION
We have determined the effect of thyroid hormones on the human UCP3 gene.
The study of the regulation of the UCP3 gene in humans is particularly complex owing to the extremely low levels of expression in human myotubes in culture. Therefore, we created transgenic mice bearing a human P1 clone that contains the entire UCP3 gene.
The expressed transgene in mice retained the tissue-specific regulation of the UCP3 gene in humans, i.e. highly preferential expression in skeletal muscle. It is noteworthy that the human UCP3 transgene expression was almost absent in heart and brown fat, in which the rodent UCP3 gene is substantially expressed (28). This finding, together with the lack of UCP3 mRNA detection in human brown fat and extremely low levels in human heart (28;29), indicates a more strict tissue-specificity of the UCP3 gene expression in skeletal muscle in humans respect to rodents. Moreover, human UCP3
transgene expression is up-regulated by starvation, similarly to the murine UCP3 gene, which may be due to the fatty acid-mediated stimulation of human UCP3 gene transcription, as already reported (9). The results obtained after T3 administration in transgenic mice demonstrate that the human UCP3 gene is up-regulated by thyroid hormones "in vivo", in agreement with previous findings in muscle biopsies from human volunteers (11) . Most of the reported experiments in which UCP3 mRNA levels are induced by a single T3 injection were carried out in hypothyroid rats (7) . When we applied T3 to euthyroid mice, only the human UCP3 transgene was induced, but not the endogenous murine UCP3 mRNA. This suggested that the human UCP3 gene is more sensitive to thyroid-dependent stimulation than the mouse gene. The construct of the mouse UCP3 gene promoter transiently transfected to the same cells in identical conditions to those used for the human UCP3 promoter, was responsive to T3 stimulation but to a lesser extent than the human UCP3 promoter construct. Both the human and mouse UCP3 gene promoters required a similar TRE in the proximal promoter region, but the mouse TRE appeared to be weaker than the human TRE. By contrast, other features of regulation such as dependency on MyoD were equally shared by both promoters.
Thyroid hormones can induce lipolysis and fatty acid oxidation (30) and hyperthyroidism increases the levels of free fatty acids. Most of the physio-pathological situations reported to date in which UCP3 expression is modified in skeletal muscle are associated to parallel changes in fatty acid availability to skeletal muscle. The effects of fatty acids on UCP3 gene transcription are mediated by PPARα and PPARδ receptors which interact with the promoter region of the human UCP3 gene (9) . Therefore, it could not be excluded that the effects of T3 on UCP3 gene expression "in vivo" may be due to the action of fatty acids. Moreover, thyroid hormones induce master transcription factors for mitochondrial gene expression, such as nuclear respiratory factors, which can affect UCP3 gene expression (31) . However, our present results establish that the action of thyroid hormones is direct and mediated by TR binding to the proximal region of the UCP3 gene promoter. In the human promoter, the TRE element required for responsiveness is coincident with the reported site responsible for responsiveness to PPAR and retinoids, thus indicating that it behaves as a multihormonal responsive element. Moreover, the action of T3 on the human UCP3 promoter requires MyoD, as does the PPAR and RAR-dependent activation (8;9) . This confirms that MyoD acts as permissive factor for basal and hormone-dependent transcriptional activity of the human UCP3 promoter.
The finding that responsiveness to thyroid hormone shares a common DNA region with the retinoic acid and PPAR-dependent pathways suggests a cross-talk between these regulatory pathways in the human UCP3 promoter, as reported for other Activation of mitochondrial respiration by thyroid hormones results in increased reactive oxygen species production, at least in liver cells (35) , and it has been also proposed that a high production of reactive oxygen species is on the basis of muscular injury caused by hyperthyrodism (36) . In this context, induction of UCP3 gene expression by thyroid hormones could be viewed as a protective mechanism for excessive ROS production when cell respiration is enhanced by a physiological increase in these hormones.
In summary, we conclude that thyroid hormones directly activate the human and 
